Barkerville Gold {TSX.V: BGM} has reported some high grade mineralisation for the phase 2 drilling at their Cariboo Gold project, at Barkerville Mountain, B.C.
The glory hole was 43.48 G/T over 7.95 metres.
|
Carlisle Goldfields {TSX: CGJ} confirmed their acquisition by Alamos Gold {TSX. AGI} had been completed.
Votes cast in favour were over 98%.
A Final Order was granted by the
“We are very pleased to announce the closing of the Carlisle acquisition and to consolidate our ownership of the
About Alamos
Alamos is a Canadian-based intermediate gold producer with diversified production from three operating mines in
Cautionary Note
The TSX and
This News Release includes certain “forward-looking statements”. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties. These forward-looking statements are based on forecasts of future operational or financial results, estimates of amounts not yet determinable and reasonable assumptions of management. Although Alamos has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are asked to review the “Risk Factors” set out in
The price of WTI crude fell to $33.54 after close in the USA tonight, as the price falls inexorably towards the now highly expected $30 mark.
The cause for this new fall after a few days respite when the price regained some of the previous months losses may have a political rather than economic root cause.
Has political skulduggery caused the latest fall in the oil price?
After such a dramatic fall in the price of oil over the past year, a bounce was on the cards and duly occurred a couple of weeks ago, and predictions that the price had “bottomed” and “stabilised” were abundant in the media and financial press.
I did not buy the “bottom” theory, due to the rapidly slowing world economy, and the fact that the deep pocketed Saudis seem to be trying to wipe out high cost American shale oil producers, and have sufficient reserves to keep the pressure on for a lot longer.
Now a new theory has emerged, and quite a plausible one at that. This is that countries such as Italy received about 12 – 14% of their oil from Iran, which was embargoed during the dispute about their nuclear program. As a result, Saudi crude filled the void caused by the non delivery of Iranian oil.
Now that Iran is preparing to restart oil exports, they are naturally looking to supply their traditional customer such as Italy. The Saudis, who are locked in many disputes with Iran in the Middle East, want to inflict as much pain as possible, and are rumoured to have wooed the Italians with a discount offer to maintain their custom, rather than them switching back to Iran.
If this rumour is true, it not only explains the falling oil price, but raises the stakes significantly in the proxy wars being fought between these two countries. When one considers that similar action by the Kuwaiti government was the trigger for the Iraqi invasion, the danger here becomes clear.
let’s hope clear heads pull everyone back from the brink, because we seem to be edging closer every day.
Ironically, if direct hostilities commence, the price of oil is likely to escalate significantly in short order as the danger to world supplies would be immense.
Inovio Pharmaceuticals, Inc. (NASDAQ: INO} today announced they are presenting at the upcoming Biotech Showcase 2016.
This event will take place in San Francisco, 11th to the 13th January 2016.
PLYMOUTH MEETING, PA – January 5, 2016 – Inovio Pharmaceuticals, Inc. (NASDAQ: INO} today announced that Dr. J. Joseph Kim, President and CEO, will give a corporate presentation on Tuesday, January 12th at 16.30 UK time at Biotech Showcase 2016, San Francisco, USA.
Dr. Kim will also participate on a Biotech Showcase panel entitled, Investing in the Immuno-Oncology Revolution: Follow the T Cells. This panel will occur on Wednesday, January 13th at 16.00 UK time and will feature additional leaders in the immuno-oncology space.
A live and archived version of Dr. Kim’s corporate presentation will be made available through the “Webcast” tab on Inovio’s home page at www.inovio.com as well as at the following URL: http://bit.ly/1O5Z6IE.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that is generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.
For more information, visit www.inovio.com
CONTACT:
Investors: Bernie Hertel,
Inovio Pharmaceuticals,
+1 858 410 3101,
bhertel@inovio.com
# # # #
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended September 30, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 110
Plymouth Meeting Pennsylvania 19462
United States
Inovio Pharmaceutical {NASDAQ: INO} appoint Dr. Prakash Byuyan VGX-3100 Leadership Team, specifically to lead the clinical development of Inovio’s programs to treat HPV-related pre-cancers (dysplasia).
Dr. Bhuyan’s Accomplishments Include Successful Development of Vaccines at Pfizer and Merck.
Dr. Prakash Bhuyan Joins VGX-3100 Leadership Team
PLYMOUTH MEETING, Pa. − January 4, 2016 – Inovio Pharmaceuticals {NASDAQ: INO} announced today it has Dr. Bhuyan will lead the clinical development of Inovio’s programs to treat HPV-related pre-cancers (dysplasia). Inovio will take VGX-3100, its treatment for cervical dysplasia caused by the human papillomavirus (HPV), into a phase 3 registration study this year. He will report to Dr. Mark Bagarazzi, Chief Medical Officer.
Prior to joining Inovio, Dr. Bhuyan was Senior Director, Pfizer Vaccine Research, where he led the pivotal clinical study that helped achieve FDA approval in 2014 of the first meningococcal B vaccine to be licensed in the U.S.
Prior to Pfizer, Dr. Bhuyan directed the development and execution of multiple vaccine clinical trials for 4 licensed vaccines at Merck and successfully led an investigational hexavalent pediatric vaccine from phase 2 into phase 3 trials. He earned his M.D. and his Ph.D. in Immunology from the University of Texas Southwestern Medical Center. He completed his fellowship in Infectious Diseases at the University of Pennsylvania, where he currently serves as adjunct assistant professor.
Dr. Mark Bagarazzi, Chief Medical Officer, said, “Dr. Prakash Bhuyan has demonstrated leadership in advancing vaccines to licensure and we are pleased to bring him to Inovio where he will focus on advancing the development of VGX-3100. He will be instrumental in guiding VGX-3100, our immunotherapy for cervical pre-cancer, into phase 3 later this year.”
Inovio’s phase 2b trial showed that histopathological regression of high grade cervical neoplasia (CIN2/3) to low grade neoplasia (CIN1) or no disease occurred in a significantly higher percentage of VGX-3100 recipients compared with placebo recipients.
Furthermore, concomitant histopathological regression and clearance of HPV occurred in a significantly higher percentage of VGX-3100 recipients compared with placebo recipients. HPV-specific CD8+ “killer T cells” were also generated in the blood as well as a substantial infiltration of CD8+ cells in the cervical tissue of VGX-3100 recipients, underscoring the role played by Inovio’s best-in-class T-cell responses. VGX-3100 was safe and generally well-tolerated.
In VGX-3100-treated women whose high grade dysplasia regressed, most (43 out of 53) completely cleared their lesions to normal (complete response). Moreover, eighty percent of VGX-3100-treated women whose dysplasia regressed also eradicated the infecting HPV genotype (i.e. 16 or 18) from the cervix. This is an important outcome as persistence of the virus is associated with recurrence of the disease.
In 2015, The Lancet reported on results of Inovio’s phase 2b trial in an article entitled, “Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomized, double-blind, placebo-controlled phase 2b trial,” by C. Trimble, et al.
About VGX-3100
Inovio’s VGX-3100 is an immunotherapy containing two DNA plasmids targeting the E6 and E7 oncogenes of HPV types 16 and 18. These oncogenes are responsible for transforming HPV-infected cells into pre-cancerous and cancerous cells. The treatment is administered to patients by injection into muscle (typically in the arm), followed by electroporation using Inovio’s CELLECTRA® device. VGX-3100 has been shown to induce a robust immune response against the E6 and E7 oncogenes associated with HPV types 16 and 18.
About HPV and Cervical Dysplasia
Human papillomavirus (HPV) is the most common sexually transmitted disease. At any given time, approximately 11% percent of the world population is infected with HPV. Roughly 75% or less of HPV 16/18 infections are cleared by naturally occurring immune responses in women of all ages.
Persistent HPV infection can lead to dysplasia, or premalignant changes, in cervical cells. HPV types 16 and 18 cause 70% of cervical dysplasia and cervical cancer cases. Each year in the United States, 1.4 million women are diagnosed with CIN1 and 300,000-400,000 women are diagnosed with CIN2/3. All cervical cancers arise from untreated CIN2/3.
About Inovio Pharmaceuticals, Inc.
Inovio is taking immunotherapy to the next level in the fight against cancer and infectious diseases. We are the only immunotherapy company that is generating T cells in vivo in high quantity that are fully functional and whose killing capacity correlates with relevant clinical outcomes with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include MedImmune, Roche, University of Pennsylvania, DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.
For more information, visit www.inovio.com
CONTACT:
Bernie Hertel,
Inovio Pharmaceuticals,
+1 858 410 3101,
bhertel@inovio.com
# # # #
This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100 and INO-3112, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, our Form 10-Q for the quarter ended September 30, 2015, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.
Inovio Pharmaceuticals, Inc.
660 West Germantown Pike
Suite 110
Plymouth Meeting Pennsylvania 19462
United States
The execution of shia cleric Nimr al-Nimr by Suadi Arabia has heightened regional tensions in an already tense and fractious Middle East.
The result of this increased tension will likely manifest itself in higher oil and gold prices, and possibly impact share prices worldwide negatively.
The execution of a shia cleric, Nimr al-Nimr, by Saudi Arabia has ratcheted up tensions in an already powder keg situation in the Middle East.
The execution seems designed to deliberately escalate an already tense situation with Iran and Saudi Arabia already locked in proxy wars in Syria and Yemen. Any escalation into direct armed conflict would clearly jeopardise the flow of crude oil to the west, which have to pass through the Straights of Hormuz, an area that borders Iran, and at it’s narrowest point is a mere 22 miles across.
So, as a result, the price of crude will likely increase in the short term whilst the next steps are absorbed by the market, and international tension always benefits the price of gold, the preferred fallback in such situations.
The subsequent ending of diplomatic relations between Saudi Arabia and Iran does not bode well for an early resolution to this problem. In 2014 Saudi Arabia was the world’s largest buyer of military equipment, and was set to continue that trend in 2015 suggesting they are preparing for military conflict with Iran, their regional rival.
Interestingly, western governments have made a very muted response to the executions in Saudi Arabia, a barbaric act that would have surely been condemned had it been carried out by a less friendly power, say Russia.
I expect markets to become very volatile this week,as an early diplomatic solution looks very unlikely.
Nymox Pharmaceutical Corporation {NASDAQ: NYMX} Director James George Robinson has continued his recent buying spree, with two more significant purchases.
Robinson is showing a huge amount of confidence in his own company, and now holds over $9 million worth of Nymox shares at today’s market price.
Nymox Pharmaceutical Corporation {NASDAQ: NYMX} Director James George Robinson purchased 14,000 shares of the firm’s stock in a transaction on Tuesday, December 29th.
The shares were purchased at an average price of $3.55 per share, with a total value of $49,700.00. Following the completion of the acquisition, the director now directly owns 2,542,550 shares of the company’s stock, valued at $9,026,052.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
James George Robinson also recently made the following trades:
Everyone at City Investors Circle would like to wish all our readers a happy New Year, and a healthy and prosperous 2016!
We hope you enjoy a lovely evening with those close to you.
The fall in the price of oil is driving the US $ higher at the expense of the oil based currencies.
Today the Russian ruble fell to an all time low v the US$, and the Canadian $ fell as well.
The US $ strength continues as the oil price falls once again on the 2.5 million barrel increase in US inventories.
The Canadian $ is at 1.39 v the US $, a quite extraordinary rate considering how recent it was that the loonie was above par with the greenback!
The benefit of this of course is that for anyone in the mining or oil and gas industries working in Canada and exporting is being boosted by the currency fall. Costs are in Canadian $, and revenue in US $.
An example of this is coking coal, with an average price of US $80 per ton if shipped from the USA, but that same coal, would be worth CAD $112 in Canada, where the costs are in Canadian $.
This gives Canadian based miners a huge advantage over their US counterparts, and already three major coal companies are in bankruptcy protection in the USA.
Gold is currently US $1061, but in Canada a gold miner receives Canadian $ 1,485! And their costs are in Cad $! This huge advantage is not being taken into account by investors, if the price of gold was US$1,485 it would be headline news.
The price of crude sold outside Canada attracts a CAD $13 premium for a Canadian based producer exporting, and again this is not being taken into account in my view.
The Russian Ruble fell to 73 v the US $ today, an all time low, and again locally produced oil is sold in US $, whereas cost are in rubles.
Paragon Diamonds {AIM: PGN} has delisted from the AIM market.
Management finally admitted defeat in their attempts to raise finance by year end.
Comment
Another example of how brutal the resources sector is being treated by those that finance such projects.
Once again a company that would normally be able to raise finance is thrown to the wolves by the lack of institutional support.
This does not augur well for the sector in 2016.
Paragon have stated their intention to relist in due course, on either the junior or main market, as soon as is practicable after a cash injection has been secured, assuming it is of course.
Once raised, the investment will allow Paragon to develop the Lemphane project, and acquire the Mothae property, both located in Lesotho.
Terrace Energy Corporation {CVE.V: TZR} reports their earnings on December 29th.
Interestingly, in a month of low oil prices TZR has trended upwards.
Comment
It is interesting that in the last month there have been the lowest oil prices reported in years, yet Terrace has increased 6%, and is trending upwards.
It will be interesting to see if the results come up to the expectations!
Terrace Energy Corporation {CVE.V: TZR} is to reports earnings on December, 29.
The stock increased 14.29% on December 24, hitting $0.16. About 107,000 shares traded hands, or 5 times the daily average.
Terrace Energy risen 6.00% since November 27, 2015 and is in an uptrend.
Barkerville Gold Mines {TSX.V: BGM} confirmed it has closed their $6 million flow through share offering, and $3.5 million Flow through unit offering.
Under Canadian rules all flow through money has to be spent on exploration, so investors can expect a significant program going forward.
|
Nymox Pharmaceutical Corporation {NASDAQ: NYMX} Director James George Robinson has acquired 29,854 more shares in the company, adding to his recent purchases.
All three purchases in December were quite significant,and are an excellent example of a director showing confidence in his own company.
Comment
This is a superb,and sadly very rare example of a director putting substantial funds in to back his own company.
He has invested around $500,000 in December alone, he must be very confident!
Nymox Pharmaceutical Corporation {NASDAQ: NYMX} Director James George Robinson acquired 29,854 shares of the stock in a transaction purchase transaction dated Wednesday, December 23rd.
The shares were bought at an average price of $3.54 per share, with a total value of $105,683.16. Following the completion of the purchase, the director now directly owns 2,517,550 shares of the company’s stock, valued at approximately $8,912,127. The purchase was disclosed in a filing with the SEC.
James George Robinson also recently made the following trades
Nymox Pharmaceutical Corporation {NASDAQ: NYMX} traded up 5.85% on Thursday, hitting $3.62. Shares traded were 226,614.
Nymox Pharmaceutical Corp has a 52-week low of $0.35 and a 52-week high of $4.37., and their market cap is $134.61 million.
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (NASDAQ:NYMX) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer’s disease. The Company’s subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.
City Investors Circle would like to wish all our readers a very Merry Christmas and a happy, healthy, and prosperous 2016!
We hope everyone enjoys a peaceful festive period.
2016 could prove another challenging year, but there are always good investments and opportunities despite the volatility.
We hope to identify and take advantage of some of them!
Avalon Rare Metals {TSX: AVL} have raised $750,000 via a non brokered private placement.
This was a flow through issue at 12.5c per share, with a warrant priced at 17.5 cents for two years..
Avalon Completes Non-Brokered Private Placement
|
Scorpio Gold Corp. {TSX.V: SGN} have reported drill results from their State Bank project at Mineral Park, Nevada, USA.
Most holes disappointed, but two high grade mineralised intersections were reported.
________________________________________
News – Monday, December 21, 2015
Scorpio Gold Reports Results of Exploration Drilling at the State Bank Target, Mineral Ridge Project, Nevada
________________________________________
Vancouver, December 21, 2014 – Scorpio Gold Corp. {TSX.V: SGN} reports results from its 2014-2015 exploration drilling program within the State Bank target area at its 70% owned Mineral Ridge project, located in Nevada.
State Bank is a large target area located west- southwest of the Bluelite deposit. Targeting of the area was based on a combination of soil geochemistry, rock chip sampling, geophysical interpretation and aster imagery. Detailed geological and structural mapping determined that elevated gold grades correlate with fold axes, a feature common to several of the gold deposits at Mineral Ridge.
In total, 78 reverse circulation and two diamond core holes tested parts of the target area. Approximately 42% of the holes intersected mineralisation of interest; however, the majority of holes returned sub-gram gold assays. High-grade mineralisation was intersected in two holes (MR151899-900) in the southwest corner of the target area.
Follow-up drilling is planned in 2016.
Highlights from RC drilling on the State Bank target include:
• MR141071: 1.33 grams per tonne (“g/t”) gold over 9.14 meters
• MR141087: 1.89 g/t gold over 9.14 meters
• MR141088: 1.31 g/t gold over 3.05 meters
• MR141093: 2.85 g/t gold over 1.52 meters
• MR141095: 1.87 g/t gold over 3.05 meters
• MR151732: 2.51 g/t gold over 6.10 meters
• MR151899: 9.98 g/t gold over 1.52 meters
• MR151900: 17.02 g/t gold over 3.05 meters
A drill hole location map is available at the company website www.scorpiogold.com
Table 1. State Bank Target Area – Significant Drill Results
| Hole No. |
Azm (deg) |
Dip (deg) |
From (ft) |
To (ft) |
Width (ft) |
From (m) |
To (m) |
Width (m) |
Gold (OPT) |
Gold (g/t) |
|---|---|---|---|---|---|---|---|---|---|---|
| MR141013 | 300 | -60 | No Significant Results | |||||||
| MR141014 | 300 | -65 | 37 | 45 | 8 | 11.28 | 13.72 | 2.44 | 0.027 | 0.92 |
| MR141070 | 0 | -90 | 725 | 730 | 5 | 220.98 | 222.50 | 1.52 | 0.015 | 0.50 |
| MR141071 | 0 | -90 | 25 | 30 | 5 | 7.62 | 9.14 | 1.52 | 0.039 | 1.33 |
| 350 | 355 | 5 | 106.68 | 108.20 | 1.52 | 0.019 | 0.64 | |||
| MR141072 | 0 | -90 | No Significant Results | |||||||
| MR141073 | 0 | -90 | 230 | 235 | 5 | 70.10 | 71.63 | 1.52 | 0.013 | 0.45 |
| 345 | 355 | 10 | 105.16 | 108.20 | 3.05 | 0.021 | 0.71 | |||
| MR141074 | 0 | -90 | 30 | 35 | 5 | 9.14 | 10.67 | 1.52 | 0.011 | 0.37 |
| 55 | 70 | 15 | 16.76 | 21.34 | 4.57 | 0.014 | 0.47 | |||
| 345 | 355 | 10 | 105.16 | 108.20 | 3.05 | 0.014 | 0.50 | |||
| 365 | 400 | 35 | 111.25 | 121.92 | 10.67 | 0.022 | 0.77 | |||
| MR141075 | 0 | -90 | 310 | 315 | 5 | 94.49 | 96.01 | 1.52 | 0.024 | 0.82 |
| MR141076 | 0 | -90 | 260 | 265 | 5 | 79.25 | 80.77 | 1.52 | 0.022 | 0.74 |
| MR141077-079 | 0 | -90 | No Significant Results | |||||||
| MR141080 | 0 | -90 | 110 | 115 | 5 | 33.53 | 35.05 | 1.52 | 0.010 | 0.34 |
| 185 | 190 | 5 | 56.39 | 57.91 | 1.52 | 0.043 | 1.47 | |||
| MR141081-082 | 0 | -90 | No Significant Results | |||||||
| MR141083 | 0 | -90 | 20 | 25 | 5 | 6.10 | 7.62 | 1.52 | 0.023 | 0.77 |
| MR141084 | 0 | -90 | 95 | 100 | 5 | 28.96 | 30.48 | 1.52 | 0.018 | 0.62 |
| MR141085 | 0 | -90 | 20 | 25 | 5 | 6.10 | 7.62 | 1.52 | 0.023 | 0.77 |
| MR141086 | 0 | -90 | No Significant Results | |||||||
| MR141087 | 0 | -90 | 20 | 50 | 30 | 6.10 | 15.24 | 9.14 | 0.055 | 1.89 |
| MR141088 | 0 | -90 | 20 | 30 | 10 | 6.10 | 9.14 | 3.05 | 0.038 | 1.31 |
| MR141089-090 | 0 | -90 | No Significant Results | |||||||
| MR141091 | 0 | -90 | 180 | 185 | 5 | 54.86 | 56.39 | 1.52 | 0.010 | 0.34 |
| MR141092 | 0 | -90 | No Significant Results | |||||||
| MR141093 | 0 | -90 | 115 | 120 | 5 | 35.05 | 36.58 | 1.52 | 0.083 | 2.85 |
| MR141094 | 0 | -90 | 25 | 30 | 5 | 7.62 | 9.14 | 1.52 | 0.011 | 0.38 |
| 50 | 55 | 5 | 15.24 | 16.76 | 1.52 | 0.016 | 0.55 | |||
| 65 | 70 | 5 | 19.81 | 21.34 | 1.52 | 0.039 | 1.34 | |||
| 135 | 140 | 5 | 41.15 | 42.67 | 1.52 | 0.036 | 1.23 | |||
| MR141095 | 0 | -90 | 40 | 50 | 10 | 12.19 | 15.24 | 3.05 | 0.042 | 1.42 |
| 90 | 100 | 10 | 27.43 | 30.48 | 3.05 | 0.055 | 1.87 | |||
| MR141096-098 | 0 | -90 | No Significant Results | |||||||
| MR141099 | 0 | -90 | 35 | 40 | 5 | 10.67 | 12.19 | 1.52 | 0.020 | 0.69 |
| 380 | 385 | 5 | 115.82 | 117.35 | 1.52 | 0.019 | 0.65 | |||
| MR151581 | 0 | -90 | 25 | 40 | 15 | 7.62 | 12.19 | 4.57 | 0.011 | 0.39 |
| MR151582 | 300 | -60 | 35 | 40 | 5 | 10.67 | 12.19 | 1.52 | 0.047 | 1.61 |
| MR151583,585 | 300 | -60 | No Significant Results | |||||||
| MR151584 | 300 | -60 | 15 | 20 | 5 | 4.57 | 6.10 | 1.52 | 0.019 | 0.65 |
| 45 | 50 | 5 | 13.72 | 15.24 | 1.52 | 0.023 | 0.79 | |||
| MR151586 | 300 | -60 | 40 | 45 | 5 | 12.19 | 13.72 | 1.52 | 0.022 | 0.75 |
| MR151587,590 | 0 | -90 | No Significant Results | |||||||
| MR151588 | 0 | -90 | 310 | 315 | 5 | 94.49 | 96.01 | 1.52 | 0.018 | 0.62 |
| MR151589 | 0 | -90 | 235 | 240 | 5 | 71.63 | 73.15 | 1.52 | 0.013 | 0.45 |
| MR151591 | 0 | -90 | 140 | 145 | 5 | 42.67 | 44.20 | 1.52 | 0.013 | 0.45 |
| MR151592-597 | 0 | -90 | No Significant Results | |||||||
| MR151713,715 | 0 | -90 | No Significant Results | |||||||
| MR151719-721 | 0 | -90 | No Significant Results | |||||||
| MR151722 | 0 | -90 | 245 | 250 | 5 | 74.68 | 76.20 | 1.52 | 0.012 | 0.41 |
| MR151729-731 | 0 | -90 | No Significant Results | |||||||
| MR151732 | 0 | -90 | 215 | 235 | 20 | 65.53 | 71.63 | 6.10 | 0.073 | 2.51 |
| MR151733 | 0 | -90 | No Significant Results | |||||||
| MR151897-898 | 0 | -90 | No Significant Results | |||||||
| MR151899 | 0 | -90 | 150 | 155 | 5 | 45.72 | 47.24 | 1.52 | 0.291 | 9.98 |
| 190 | 200 | 10 | 57.91 | 60.96 | 3.05 | 0.017 | 0.58 | |||
| MR151900 | 0 | -90 | 135 | 145 | 10 | 41.15 | 44.20 | 3.05 | 0.497 | 17.02 |
| incl | 135 | 140 | 5 | 41.15 | 42.67 | 1.52 | 0.949 | 32.54 | ||
| 175 | 180 | 5 | 53.34 | 54.86 | 1.52 | 0.053 | 1.82 | |||
| MR151902 | 0 | -90 | 150 | 160 | 10 | 45.72 | 48.77 | 3.05 | 0.015 | 0.51 |
| MR151903 | 0 | -90 | 180 | 185 | 5 | 54.86 | 56.39 | 1.52 | 0.012 | 0.41 |
| MR151901,904 | 0 | -90 | No Significant Results | |||||||
| MR151905-910 | 0 | -90 | No Significant Results | |||||||
| MR151911 | 0 | -90 | 10 | 15 | 5 | 3.05 | 4.57 | 1.52 | 0.018 | 0.62 |
| 210 | 215 | 5 | 64.01 | 65.53 | 1.52 | 0.018 | 0.62 | |||
| MR151912-913 | 0 | -90 | No Significant Results | |||||||
| MR151914 | 0 | -90 | 230 | 235 | 5 | 70.10 | 71.63 | 1.52 | 0.015 | 0.51 |
| MR151915-917 | 0 | -90 | No Significant Results | |||||||
All holes presented in Table 1 were completed by reverse circulation (RC) drilling with the exception of core holes MR141013-14. True width is estimated at 80-100% of downhole width. Analytical results were performed by American Assay Laboratory Inc. in Sparks, Nevada, an ISO/IEC 17025:2005 accredited facility. External check assays to verify lab accuracy are routinely completed by ALS Chemex, an ISO 9001:2000 certified and ISO/IEC 17025:2005 accredited facility. Further details are presented in the Company’s quality assurance and quality control program for the Mineral Ridge project available at: leted by ALS Chemex, an ISO 9001:2000 certified and ISO/IEC 17025:2005 accredited facility. Further details are presented in the Company’s quality assurance and quality control program for the Mineral Ridge project available at: MR QAQC.
About Scorpio Gold
Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Elevon, LLC (30%). Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property in Manhattan, Nevada, with a fully permitted underground mine and 400 ton per day mill facility. The Goldwedge mill facility has been placed on a care and maintenance basis and can be restarted immediately when needed.
Scorpio Gold’s President & CEO, Peter J. Hawley, PGeo,, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.
ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION
Peter J. Hawley,
President & CEO
For further information contact:
Peter J. Hawley, CEO
Tel: +1 819 825 7618
Email: phawley@scorpiogold.com
Website: www.scorpiogold.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
The Company relies on litigation protection for forward-looking statements. This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “suggest”, “indicate” and other similar words or statements that certain events or conditions “may” or “will” occur, and include, without limitation, statements regarding the Company’s plans with respect to the exploration, development and exploitation of its Mineral Ridge project, including additional drilling in the State Bank target area in 2016. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks involved in mineral exploration and development programs and those risk factors outlined in the Company’s Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.
________________________________________
Copyright © 2012 SCORPIO GOLD CORPORATION (TSX: SGN) All rights reserved. For more information visit our website at http://www.scorpiogold.com/ or send email to scorpio@scorpiogold.com
________________________________________
Avalon Rare Metals {TSX. AVL} has successfully listed on the US exchange OTCQX, Bulletin markets.
THE OTCQX listing allows American based investors to trade shares in Canadian securities, under the regulation of the TMX.
OTC MARKETS BULLETIN: OTC Markets Group Welcomes Avalon Rare Metals to OTCQX
December 21, 2015
OTC Markets Group Inc. {OTCQX: OTCM} and operator of Open, Transparent and Connected financial markets, announces Avalon Rare Metals Inc. {TSX: AVL; OTCQX: AVLNF}, a Canadian mineral development company, has qualified to trade on the OTCQX® Best Market. (Avalon previously traded on the NYSE).
Avalon began trading on December 18, 2015 on OTCQX under the symbol “AVLNF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com
“We are thrilled to welcome Avalon to the family of established, investor-focused companies on the OTCQX market,” said Jason Paltrowitz, Executive Vice President of OTC Markets Group. “Trading on OTCQX will allow Avalon to continue to provide a high-quality trading and information experience for its investors without the high cost and regulatory complexity of a U.S. exchange listing. We look forward to helping Avalon prosper and thrive.”
“Avalon’s President and CEO Don Bubar commented, “We are pleased to be able to maintain a U.S. trading market and continued market access for U.S. investors. The OTCQX market is an effective alternative for Avalon that has grown considerably since the company first began trading there in 2009.”
Dorsey & Whitney LLP serves as Avalon’s Principal American Liaison (“PAL”) on OTCQX, responsible for providing professional guidance on OTCQX requirements.
About OTC Markets Group Inc.
OTC Markets Group Inc. operates Open, Transparent and Connected financial markets for 10,000 U.S. and global securities. Through its OTC Link® ATS, they directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities. OTC Markets Group organizes these securities into markets to inform investors of opportunities and risks: the OTCQX® Best Market; the OTCQB® Venture Market; and the OTC Pink® Open Market. The data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors.
About Avalon Rare Metals Inc.
Avalon Rare Metals Inc. is a Canadian mineral development company specializing in niche market metals and minerals with growing demand in new technology. Avalon has three advanced stage projects, all 100%-owned, providing investors with exposure to lithium, tin and indium, as well as rare earth elements, tantalum, niobium, and zirconium. Avalon is currently focusing on its Separation Rapids Lithium Project, Kenora, ON and its East Kemptville Tin-Indium Project, Yarmouth, NS. Social responsibility and environmental stewardship are corporate cornerstones.
For questions or feedback, please email Avalon at ir@avalonraremetals.com
Contact
130 Adelaide St. W, Suite 1901
Toronto,
ONTARIO M5H 3P5
+1 416 364-4938
ir@avalonraremetals.com
Nymox Pharmaceutical Corp. {NASDAQ:NYMX} updated shareholders at their Annual General Meeting, held in Nassau, Bahamas.
Nassau is the new registered office of the company.
Nymox Provides Update From Shareholders Annual General Meeting December 16
HASBROUCK HEIGHTS, NJ (December 17, 2015) Nymox Pharmaceutical Corp. {NASDAQ:NYMX} is pleased to report an update on the Corporation’s business as of December 16, 2015.
At the Company’s AGM in Nassau, the following highlights were presented:
• The Company is moving forward with the activities of preparing for filing for approval of fexapotide triflutate (NX-1207) 2.5 mg for the treatment of prostate enlargement (BPH). The Company is pleased with the solid progress that has been made. The date(s) of anticipated filing will be reported in due course.
Dr. Paul Averback, CEO said “Our management team has over the past several months been very focused on taking the necessary steps that will allow our Company to file for regulatory approvals for fexapotide triflutate in various markets. We expect to provide an update in the near future with regard to the filing for approval for our BPH drug fexapotide triflutate.”
Phase 3 trial results for fexapotide showed excellent safety profile and after 3.5 years statistically significant increased improvement in symptom scores vs placebo; statistically significant increases in responder rates vs placebo; statistically significant decrease (after 2 years) in need for surgery vs placebo; and statistically significant better nocturia outcomes vs placebo. Fexapotide is associated with a decrease in prostate cancer risk.
By comparison, some commonly used approved BPH treatments have been linked to increased cancer risk. Fexapotide has enhanced compliance and patient convenience compared to oral medications. Fexapotide is given as a single painless office treatment injectable. Approved oral medications generally involve daily pills intended for the rest of the patient’s life.
• The 18 month low grade localized prostate cancer trial of fexapotide 2.5 mg and 15 mg has been completed, and results are nearing completion of analysis. The timing of reporting of results is on target and top-line data will be presented in the very near future. In corporate developments, Richard Cutler of Houston, TX was appointed to the Board of Directors. Richard Cutler is a graduate of Brigham Young University and Columbia University School of Law. Mr. Cutler has worked at several major national law firms, and in 1996, formed Cutler Law Group in Newport Beach, California and subsequently Atlanta, Georgia and Houston, Texas, a firm which specializes in corporate and securities law, as well as international business transactions.
Dr. Averback, Randall Lanham, Professor David Morse, and James G. Robinson were re-appointed to the Board of Directors. Paul McDonald has retired from the Board. The Company gratefully acknowledges Mr. McDonald’s steadfast, popular and highly valued solid service on the Board of Directors since 2006.
With reference to the Company’s quarterly financial filings, the international clients of Cutler & Co. have been acquired by transfer of responsibility to Thayer & O’Neal of Houston, Texas. Due to this recent transfer the Company’s quarterly filings have been slightly delayed and will be filed in the very near term.
For more information please contact info@nymox.com
NEWS RELEASE Forward Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Nymox, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the need for new options to treat BPH and prostate cancer, the potential of fexapotide to treat BPH and prostate cancer and the estimated timing of further developments for fexapotide. Such forward-looking statements involve substantial risks and uncertainties that could cause our clinical development program, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the clinical drug development process, including the regulatory approval process, the timing of Nymox’s regulatory filings, Nymox’s substantial dependence on fexapotide, Nymox’s commercialization plans and efforts and other matters that could affect the availability or commercial potential of fexapotide. Nymox undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Nymox in general, see Nymox’s current and future reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F for the year ended December 31, 2014, and its Quarterly Reports.
Contact:
Paul Averback Nymox Pharmaceutical Corporation
www.nymox.com
Carlisle Goldfields Limited {TSX.V: CGJ} has announced that their shareholders have overwhelmingly approved the transaction with Alamos Gold.
The deal is now subject to court approval on 21st December.
TORONTO, ON , Dec 17, 2015 — Carlisle Goldfields Limited {TSX.V: CGJ} is pleased to announce that Carlisle shareholders voted overwhelmingly to approve the plan of arrangement pursuant to which Alamos Gold Inc. (“Alamos”) will acquire all of the issued and outstanding common shares of Carlisle in exchange for: (i) 0.0942 of an Alamos common share for each Carlisle common share held, plus (ii) 0.0942 of a warrant to purchase Alamos common shares at an exercise price of C$10.00 with an expiration date of three years from closing of the transaction (the “Arrangement”).
At the special meeting of shareholders held yesterday, December 16, 2015 (the “Meeting”), 61.41% of the issued and outstanding Carlisle common shares voted in person or by proxy, of which 98.21% of the Carlisle common shares voted in favour of the Arrangement. In addition, on a vote by Carlisle shareholders, excluding those shareholders who are “interested parties” within the meaning of Multilateral Instrument 61-101 — Protection of Minority Security Holders in Special Transactions, 96.68% of the votes cast in person or by proxy were voted in favour of the Arrangement.
Carlisle’s President and Chief Executive Officer, Abraham Drost commented that: “We are gratified by the strong support of Carlisle’s shareholders for the transaction with Alamos. This transaction marks the culmination of the vision of our Chairman Bruce Reid. Subject to the final closing, we wish Alamos Gold, our First Nation stakeholders and the town of Lynn Lake all the very best with the future development of the Lynn Lake assets.”
Carlisle will apply for a final order approving the Arrangement from the Ontario Superior Court of Justice (Commercial List) on December 21, 2015. If all conditions to completion of the Arrangement are satisfied, it is anticipated that the Arrangement will become effective on or about January 7, 2016.
Copies of the meeting materials, and certain related documents with respect to the Arrangement, are available on SEDAR at www.sedar.com and on the Company’s website.
About CarlisleGoldfields
Carlisle Goldfields Limited is a gold exploration and development company focused, together with its joint venture partner, Alamos Gold Inc., on pursuing a definitive feasibility study (“DFS”) evaluation of the Lynn Lake Gold Camp in Lynn Lake, Manitoba, Canada. Carlisle previously completed NI 43-101 compliant mineral resource estimates on five (5) deposits within its Lynn Lake Gold Camp, four (4) of which form the basis for the February, 2014 Preliminary Economic Assessment (PEA) technical report (Farley Lake Mine Deposit, MacLellan Mine Deposit, Burnt Timber Mine Deposit, and Linkwood Deposit). A second PEA technical report filed in April, 2014 focused on an open pit mining and processing model for the historical Farley Lake Mine and MacLellan Mine deposits only.
Cautionary Note
This News Release includes certain “forward-looking statements”, including information pertaining to completion of the acquisition of Carlisle by Alamos. All statements other than statements of historical fact included in this release are forward-looking statements that involve various risks and uncertainties. These forward-looking statements are based on reasonable assumptions of management, including receipt of court approval required for the acquisition of Carlisle by Alamos.
Although Carlisle has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are asked to review the “Risk Factors” relating to the Arrangement set out in Carlisle Goldfields Limited’s Management Proxy Circular prepared for the Meeting and other filings available on SEDAR. There can be no assurance that forward-looking statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
FOR FURTHER INFORMATION PLEASE CONTACT:
CARLISLE GOLDFIELDS LIMITED
2702 – 401 BAY STREET
TORONTO,
ONTARIO,
CANADA
info@carlislegold.com
Abraham Drost President & CEO
+1 807-252-7800
adrost@carlislegold.com
Bruce Reid Executive Chairman
+1 647-500-4495
br@carlislegold.com
SOURCE: Carlisle Goldfields Limited
Range Energy {CSE: RGO} confirm the issuance of 75 million shares at 4c each to raise up to $3 million to maintain their position at Khalakan in good standing, and for general working capital purposes.
The litigation halt between Range and their partners at Khalakan has now expired, but the parties remain in talks to extend the truce or secure a permanent one.
Range arranges financing, litigation halt expires
2015-12-16 17:33 ET – News Release
Mr. Toufic Chahine reports
NON-BROKERED PRIVATE PLACEMENT FINANCING AND CORPORATE UPDATE
Range Energy Resources Inc. {CSE: RGO} has arranged a non-brokered private placement of up to 75 million units of the company at a price of four cents per unit for gross proceeds of up to $3-million. Each unit will consist of one common share and one transferable share purchase warrant. Each warrant will entitle the holder thereof to purchase one additional common share for a period of five years from the closing date of the offering at a price of five cents per common share.
The closing of the offering is subject to receipt of all necessary regulatory and board approvals. The securities issued pursuant to the offering will be subject to a four-month hold period in accordance with applicable Canadian securities laws. The company anticipates that there will likely be insider participation in the offering.
The capital from the offering will be used by the company to continue to fulfill its obligations to joint venture participants so that the development of the Khalakan block in the Kurdistan region of Iraq can continue, as well as provide general working capital.
The agreement to temporarily suspend litigation announced on Sept. 1, 2015, has now expired, although the parties remain in discussion for a longer or more permanent settlement agreement.
